Veterinary Drug terms — page 12 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Inositol D-Inositol; myo-inositol; inositol; Scyllo-inositol; Muco-Inositol; epi-Inositol; i-Inositol; Allo-inositol; meso-Inositol; 87-89-8; 1D-Chiro-inositol; 1L-Chiro-inositol; 488-59-5; 643-12-9; Myoinositol; Scyllitol; cis-Inositol; D-chiro-Inositol; D-(+)-chiro-Inositol; Meat sugar; mesoinositol; Neo-inositol; 6917-35-7; cyclohexane-1,2,3,4,5,6-hexol; Myoinosite; Quercinitol; Dambose; Cyclohexane-1,2,3,4,5,6-hexaol; Cocositol; Inositene; InositiPhaseomannite; Phaseomannitol; Inosital; Iso-inositol; Cyclohexitol; 551-72-4; Mesoinosit; Mesoinosite; Scyllite; Inosite; Mesovit; Nucite; Mesol; 488-58-4; L-chiro-Inositol; chiro-inositol; Cyclohexanehexol; Inositol, meso-; Inositol, myo-; Hexahydroxycyclohexane; D-myo-Inositol; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; Bios I; Insitolum; Isoinositol; (-)-Inositol; 41546-34-3; 643-10-7; d-Inositol; L-Inositol; L-myo-Inositol; Inositol, i-; Inositol (VAN); 488-55-1; D-chiro Inositol; Inositol, allo-; Inositol, muco-; L-(-)-chiro-Inositol; 1D-myo-Inositol; 1L-myo-Inositol; (+)-Inositol; 1,2,3,4,5,6-Cyclohexanehexol; Rat antispectacled eye factor; Levoinositol; CCRIS 6745; AZD 103; Inositol, epi-; Inositol, scyllo-; UNII-63GQX5QW03; UNII-8LQ63P85IC; UNII-9O6Y5O4P9W; UNII-R1Y9F3N15A; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; MFCD00077932; ELND005; 1,3,5/2,4,6-Hexahydroxycyclohexane; UNII-4661D3JP8D; UNII-6R79WV4R10; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1-L-chiro-Inositol; (-)-chiro-Inositol; UNII-1VS4X81277; CHEBI:17268; AI3-16111; NSC8101; 1,3,5/2,4,6-cyclohexanehexol; UNII-4L6452S749; UNII-587A93P465; 1,2,3,5/4,6-Cyclohexanehexol; NSC 8101; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; EINECS 201-781-2; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; NSC404118; Inositol, myo- (8CI); 576-63-6; 1,2,3,4,5,6-Hexahydroxycyclohexane; NSC 404118; 63GQX5QW03; 8LQ63P85IC; 9O6Y5O4P9W; R1Y9F3N15A; 488-54-0; MI; CHEBI:10642; CHEBI:23927; CHEBI:27372; CHEBI:27987; CDAISMWEOUEBRE-CDRYSYESSA-N; CDAISMWEOUEBRE-UHFFFAOYSA-N; 4661D3JP8D; 6R79WV4R10; Inositol (VAN8C; NSC-8101; NSC45517; NSC55551; NSC55552; NSC-25142; NSC-55551; UNII-M94176HJ2F; 1VS4X81277; NSC-404118; INS; Inositol, 98+%; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; NCGC00159409-02; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; 4L6452S749; 587A93P465; DSSTox_CID_3146; DSSTox_RID_76890; DSSTox_GSID_23146; 38876-99-2; 1,3,4,5,6-Cyclohexanehexol; 1,3,5/4,6-Cyclohexanehexol; alloinositol; neoinositol; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; 1,2,4/3,5,6-cyclohexanehexol; Mouse antialopecia factor; 1,2,3,4,5,6-Cyclohexanehexol #; cis-1,2,3,4,5,6-cyclohexanehexol; Inositol, cis-; Inositol, neo-; CAS-87-89-8; cis-1,3,5-trans-4,6-Cyclohexanehexol; SMR000857145; SMR000857319; SMR000857320; M94176HJ2F; Inositol NF 12; SR-05000001655; Chiro-inositol, (-)-; inositols; Matezodambose; Inositol [Nonspecific isomer]; Muscle sugar; ELND 005; inositol myo-; Inositol FCC; 4irx; Inositol, chiro-; rac-chiro-inositol; Inosital (TN); CBU; Inositol (USAN); EINECS 207-681-5; EINECS 207-682-0; EINECS 209-000-7; EINECS 211-393-5; EINECS 211-394-0; EINECS 230-024-9; MFCD00065455; NSC 25142; EPIINOSITOL; (+)-Epi-Inositol; (+)-Chiro-Inositol; Epi-inositol, 98%; allo-Inositol, 97%; Inositol [USAN:NF]; INOSITOL, MESO; Spectrum_001595; 2os9; orthorhombic myo-inositol; D-(+)-Chiro Inositol; J101.890F; J101.891D; Chiro-inositol, (+)-; INOSITOL (D); INOSITOL (L); Spectrum3_001053; Spectrum4_001193; Spectrum5_000961; myo-Inositol, >=99%; bmse000102; bmse000103; bmse000113; bmse000901; bmse000922; Epitope ID:144993; scyllo-Inositol, >=98%; SCHEMBL5831; SCHEMBL5832; SCHEMBL5969; NCIOpen2_008191; BSPBio_002606; KBioGR_001885; KBioSS_002075; KSC225S4P; MLS001332377; MLS001332378; MLS001335965; MLS001335966; MLS001335967; MLS001335968; SCHEMBL187278; SCHEMBL187397; SCHEMBL187796; SCHEMBL188106; SCHEMBL188237; SCHEMBL491333; SCHEMBL959404; SCHEMBL959405; CHEMBL122705; CHEMBL278373; CHEMBL468154; ELND-005; GTPL4495; GTPL4645; GTPL4648; GTPL4649; MEGxp0_001817; SCHEMBL1055883; SCHEMBL4748543; SCHEMBL6378921; SCHEMBL6468882; SCHEMBL6791918; CHEMBL1222251; CHEMBL1231671; CHEMBL1950780; CHEMBL3976780; DTXSID7023146; SCHEMBL12371461; SCHEMBL12377889; SCHEMBL12411898; SCHEMBL12711208; SCHEMBL12735687; SCHEMBL13058696; SCHEMBL13114115; SCHEMBL13114116; SCHEMBL13114128; SCHEMBL13207905; SCHEMBL13580047; SCHEMBL14542470; SCHEMBL21388397; ACon1_002457; CHEBI:22357; CHEBI:23311; CHEBI:24848; CHEBI:25492; CHEBI:27374; CTK1C5947; CTK8B3795; D-(+)-chiro-Inositol, 95%; KBio2_002075; KBio2_004643; KBio2_007211; KBio3_001826; L-(-)-chiro-Inositol, 95%; AZD-103; DTXSID30110000; DTXSID50905091; DTXSID60903982; myo-Inositol, p.a., 98.0%; CDAISMWEOUEBRE-GNIYUCBRSA-N; CDAISMWEOUEBRE-GPIVLXJGSA-N; CDAISMWEOUEBRE-LOLGQZEGSA-N; CDAISMWEOUEBRE-NIPYSYMMSA-N; CDAISMWEOUEBRE-OQYPVSDDSA-N; 1,2,3,4,5/6-cyclohexanehexol; 1,2,3,4/5,6-cyclohexanehexol; 1,2,3/4,5,6-cyclohexanehexol; 1,2,4,5/3,6-cyclohexanehexol; HMS2091N13; HMS2230N03; HMS2235H05; HMS2235M23; HMS3369B06; HMS3369F20; HMS3373E05; Pharmakon1600-01500352; 1,2,3,4,5,6-Cyclohexanehexaol; BCP25172; HY-B1411; HY-N3021; KS-00000QA9; KS-000017FC; NSC25142; NSC55558; ZINC1530357; Tox21_111642; Tox21_302035; 6643AB; ANW-43204; CC-093; CCG-36096; cis-Inositol, >=98.0% (TLC); KM0846; MFCD00272608; NSC-45517; NSC-55552; NSC-55558; NSC103959; NSC127230; NSC757076; s4530; STL453612; epi-Inositol, >=98.0% (HPLC); 1,2,3,4,5,6/0-cyclohexanetetrol; AKOS006240678; AKOS006332036; AKOS015895894; AKOS015912905; AKOS015912934; AKOS015960429; AKOS015960633; AKOS015994742; AKOS024318869; Tox21_111642_1; ZINC100018867; ZINC100019018; ZINC100024490; ZINC100032893; ZINC100035580; ZINC100037751; ZINC100055570; ZINC100073149; ZINC100513675; ZINC101185827; ZINC102201844; ZINC103574430; ZINC103574467; ZINC103574475; ZINC250615063; ZINC253837650; ZINC306121118; CS-4782; CS-W010757; DB03106; DB13178; DB15350; FCH1118762; HY-W010041; KS-1284; KS-1420; LS-2350; MCULE-2727773046; NSC-103959; NSC-127230; NSC-757076; TRA0065469; VC30505; KS-0000146H; TRA-0204644; D-chiro-Inositol, >=98.0% (HPLC); NCGC00159409-03; NCGC00159409-04; NCGC00169828-01; NCGC00178580-01; NCGC00178580-03; NCGC00255362-01; AC-11070; AK102790; AK546883; AS-10616; AS-68396; AS-68424; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; K572; NCI60_041778; SC-18136; SC-91157; SY060836; myo-Inositol, purum, >=98.0% (HPLC); rac-chiro-1,2,3,4,5,6-cyclohexanehexol; SBI-0051369.P003; AB0014290; AX8234329; DB-051583; DB-051584; DB-054642; myo-Inositol, for microbiology, >=99.0%; TR-016439; TR-017741; TR-019452; TR-022051; TR-022053; 4CH-024633; CS-0023004; FT-0627237; FT-0632208; FT-0632209; FT-0632730; FT-0652045; FT-0670357; FT-0693444; FT-0693614; I0040; I0628; I0629; I0630; I0631; I0632; I0633; S6176; ST24024704; ST24049158; ST50406013; KS-00001292; KS-00001315; myo-Inositol, BioUltra, >=99.5% (HPLC); myo-Inositol, SAJ special grade, >=99.0%; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; 3635-EP2280282A1; 3635-EP2289886A1; 3635-EP2292088A1; 3635-EP2295417A1; 3635-EP2295437A1; 3635-EP2298312A1; 3635-EP2298775A1; 3635-EP2305636A1; 3635-EP2305677A1; 3635-EP2305682A1; 3635-EP2308879A1; C00137; C06151; C06152; C06153; C19891; D08079; I-6500; K-9876; M01914; 12513-EP2277880A1; 12513-EP2277881A1; 12513-EP2292597A1; 12513-EP2292610A1; 12513-EP2298744A2; 12513-EP2298768A1; 12513-EP2305825A1; 12513-EP2316831A1; 12513-EP2374790A1; 13719-EP2269977A2; 13719-EP2280010A2; 13719-EP2289891A2; 13719-EP2295437A1; 13719-EP2298734A2; 13719-EP2298775A1; 13719-EP2308875A1; 13719-EP2311831A1; 13719-EP2316836A1; 40032-EP2298312A1; 40032-EP2311830A1; AB00051982_13; 643C129; A834712; A836375; Q407997; Q743661; Q-201583; Q2838375; Q2974313; Q3011024; Q3023527; Q3205874; Q3331426; Q3347078; Q3589114; SR-05000001655-1; SR-05000001655-5; W-202861; W-202862; W-203081; W-203168; W-203392; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexol; D-MYO-INOSITOL-1,2,5,6-TETRAPHOSPHATE SODIUM SALT; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexaol; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, United States Pharmacopeia (USP) Reference Standard; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; 2H3; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; Inositol; 1,2,3,4,5,6-Cyclohexanehexol
Iodipamide 3,3'-[(1,6-Dioxo-1,6-hexanediyl)diimino]bis[2,4,6-triiodobenzoic acid; Iodipamide; 4-14-00-01122 (Beilstein Handbook Reference)
Iodobenzene IODOBENZENE; 591-50-4; Benzene, iodo-; Phenyl iodide; Benzene iodide; Iodinebenzol; Iodo-benzene; IODOPHENYL; 1-Iodobenzene; PHENYLIODIDE; Iodo benzene; 4-iodobenzene; UNII-9HK5L7YBBR; C6H5I; Iodobenzene, 98%; NSC 9244; EINECS 209-719-6; 9HK5L7YBBR; AI3-16898; SNHMUERNLJLMHN-UHFFFAOYSA-N; iodanylbenzene; iodiobenzene; iodobenezene; phenyl-iodide; 3-iodobenzene; benzene, iodo; 2-iodo-benzene; HSDB 7859; MFCD00001029; IDOBENZENE; PubChem3921; 104130-35-0; ACMC-1ATSF; SCHEMBL1587; KSC270G7T; CHEMBL116296; PARAGOS 510022; DTXSID8060452; CTK1H0379; TIMTEC-BB SBB040910; NSC9244; LABOTEST-BB LTBB002078; BCP22486; EBD41928; KS-000000FF; NSC-9244; STR02365; ZINC1699878; AKOS BBS-00004395; ANW-33176; STL453620; AKOS000118942; AS02214; CS-W008603; DB02252; MCULE-7469705320; RTR-037196; TRA0010567; AK-88660; Iodobenzene, puriss., >=99.0% (GC); LS-30382; SC-05582; DB-029918; ST2413138; TR-037196; FT-0627260; I0050; 9604-EP2287141A1; 9604-EP2308872A1; 9604-EP2316829A1; M-6085; 72788-EP2272813A2; 72788-EP2275395A2; 72788-EP2284157A1; 72788-EP2284920A1; 72788-EP2295503A1; 72788-EP2301921A1; 72788-EP2305769A2; 72788-EP2308880A1; 72788-EP2309584A1; A832185; Q420839; F1908-0074; InChI=1/C6H5I/c7-6-4-2-1-3-5-6/h1-5; AI3-16898
Iodoform IODOFORM; Triiodomethane; 75-47-8; Methane, triiodo-; Carbon triiodide; Jodoform; CHI3; Trijodmethane; Dezinfekt V; Jodoform [Czech]; NCI-C04568; Trijodmethane [Czech]; CCRIS 346; UNII-KXI2J76489; HSDB 4099; EINECS 200-874-5; NSC 26251; AI3-52396; CHEBI:37758; OKJPEAGHQZHRQV-UHFFFAOYSA-N; KXI2J76489; MFCD00001069; NSC-26251; Iodoform, 99+%; NCGC00091389-01; DSSTox_CID_743; DSSTox_RID_75765; DSSTox_GSID_20743; CAS-75-47-8; Iodoform [JAN]; Iodoform [USP:JAN]; methyl triiodide; Iodoform (TN); tris(iodanyl)methane; Iodoform, 99%; ACMC-20akq1; WLN: IYII; Iodoform (JP17/USP); Iodoform, SAJ first grade; KSC377O0R; CHEMBL1451116; DTXSID4020743; CTK2H7708; EBD19519; KS-00000W4C; NSC26251; ZINC6827595; Tox21_111124; Tox21_202389; Tox21_302774; AKOS009031506; Iodoform, purum, >=99.0% (AT); CM10958; DB13813; LS-1666; MCULE-5976787287; RTR-024271; TRA0080382; Iodoform, puriss., 99.0-100.5%; NCGC00091389-02; NCGC00091389-03; NCGC00256394-01; NCGC00259938-01; AS-14199; K290; SC-16447; AB1001960; TR-024271; FT-0627266; C13383; D01910; A838427; Q412393; J-650249; AI3-52396
Iodoquinol 5,7-Diiodo-8-quinolinol; iodoquinol; Diiodohydroxyquinoline; 83-73-8; 5,7-diiodoquinolin-8-ol; 5,7-Diiodo-8-quinolinol; 5,7-Diiodo-8-hydroxyquinoline; Diiodoquin; DIIODOHYDROXYQUIN; Yodoxin; Diodoquin; Sebaquin; 8-Quinolinol, 5,7-diiodo-; Diodohydroxyquin; Dijodoxichinoline; Enterodiamoebin; Diamoebin; Dinoleine; Diodoquine; Diodoxylin; Direxiode; Disoquin; Embequin; Enterosept; Floraquin; Fluoraquin; Lanodoxin; Moebiquin; Quinadome; Searlequin; Dyodin; Ioquin; Zoaquin; Di-quinol; Stanquinate; Rafamebin; 5,7-Diiodo-oxine; Ioquin suspension; Dijodoxichinolinum; 8-Hydroxy-5,7-diiodoquinoline; 5,7-Diodo-8-quinolinol; Diodoxyquinoleine; Diiodoidrossichinolina; Panaquin; Diiodohidroxiquinoleina; Diiodohydroxyquinoleine; Diiodohydroxyquinolinum; Caswell No. 354; SS 578; NSC 8704; C9H5I2NO; Diiodoidrossichinolina [DCIT]; UNII-63W7IE88K8; HSDB 3224; 5,7-Diiod-8-chinolinol [IUPAC]; Diiodohydroxyquinolinum [INN-Latin]; Diiodohydroxyquinoleine [INN-French]; EINECS 201-497-9; Diiodohidroxiquinoleina [INN-Spanish]; EPA Pesticide Chemical Code 024003; BRN 0153639; AI3-16443; MLS000069404; CHEBI:5950; 63W7IE88K8; MMV002817; NCGC00018098-04; SMR000059090; DSSTox_CID_3155; DSSTox_RID_76894; Diiodohydroxyquinoline (INN); Diiodohydroxyquinoline [INN]; DSSTox_GSID_23155; Diodoxyquinoline; CAS-83-73-8; Iodoquinol [USAN]; Iodoquinol [USAN:USP]; 5,7-Diiod-8-chinolinol; Searlewuin; Meobiquin; component of Vytone; Iodoquinol (USP); Yodoxin (TN); Spectrum_000943; 8-Quinolinol,7-diiodo-; Spectrum2_001041; Spectrum3_000470; Spectrum4_000020; Spectrum5_000872; 4,7-Diiodo-8-quinolinol; ACMC-209pt7; bmse000836; EC 201-497-9; cid_3728; SCHEMBL3460; BSPBio_002180; CBDivE_011080; KBioGR_000399; KBioSS_001423; ksc-8-193; CHEMBL86754; DivK1c_000119; SPECTRUM1500353; SPBio_000962; ARONIS008419; DTXSID6023155; 5,7-bis(iodanyl)quinolin-8-ol; BDBM66035; HMS500F21; KBio1_000119; KBio2_001423; KBio2_003991; KBio2_006559; KBio3_001400; UXZFQZANDVDGMM-UHFFFAOYSA-; NSC8704; NINDS_000119; UXZFQZANDVDGMM-UHFFFAOYSA-N; WLN: T66 BNJ GI II JQ; HMS1920H05; HMS2091N15; HMS2230G24; HMS3369C20; KUC105860N; Pharmakon1600-01500353; HY-B1400; KS-000012ZY; NSC-8704; ZINC3830942; Tox21_110823; ANW-37721; CCG-40132; CH-644; NSC757077; s4565; STK070581; AKOS000120804; Tox21_110823_1; 5,7-Diiodo-8-hydroxyquinoline, 97%; CS-4910; DB09115; Iodoquinol (5,7-Diiodoquinolin-8-ol); MCULE-6767985681; NE10458; NSC-757077; IDI1_000119; KS-0000409J; TRA-0184419; NCGC00018098-01; NCGC00018098-02; NCGC00018098-03; NCGC00018098-05; NCGC00018098-07; NCGC00021685-03; NCGC00021685-04; AK-93030; DS-17759; K494; SC-87246; SBI-0051417.P003; DB-056739; LS-142538; ST2418557; TR-054776; AM20061527; D1736; FT-0619847; ST45045165; C07636; D00581; AB00052024_12; AN-329/13210059; SR-01000002969; Q5276473; SR-01000002969-2; BRD-K75855670-001-06-8; F3034-0058; Iodoquinol, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H; Diiodohydroxyquin; 5-21-03-00296 (Beilstein Handbook Reference)
Ionophore antibiotics Polyesthers; Lasalocid; Monensin; Narasin; Salinomycin
Iopanoic acid 3-Amino-alpha-ethyl-2,4,6-triiodobenzenepropanoic acid; Iopanoic acid; 4-14-00-01741 (Beilstein Handbook Reference)
Iopromide N,N'-bis(2,3-Dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methyl-1,3-benzenedicarboxamide; Iopromide; BRN 7085608
Iotalamic acid 3-(Acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic acid; Iothalamic acid; Acide iotalamique [INN-French]
Isatin 1H-Indole-2,3-dione; Isatin; 91-56-5; 1H-Indole-2,3-dione; Indoline-2,3-dione; 2,3-Indolinedione; INDOLE-2,3-DIONE; Isatine; 2,3-Dioxoindoline; Pseudoisatin; Isatic acid lactam; Tribulin; Isotin; 2,3-Diketoindoline; Isatinic acid anhydride; 2,3-Ketoindoline; o-Aminobenzoylformic anhydride; 2,3-Dioxo-2,3-dihydroindole; 2,3-dihydro-1H-indole-2,3-dione; NSC 9262; UNII-82X95S7M06; EINECS 202-077-8; MFCD00005718; BRN 0383659; AI3-03111; 2,3-dihydroindole-2,3-dione; CHEMBL326294; CHEBI:27539; JXDYKVIHCLTXOP-UHFFFAOYSA-N; 82X95S7M06; Isatin, 98%; 1186480-61-4; 1H-benzo[d]azoline-2,3-dione; 3-Indolinedione; indol-2; Indole-2; hydroxy-3-indolone; Isatin, p.a.; 3-hydroxy-2-indolone; Isatin (Compound 1); PubChem13609; Isatin, technical grade; ACMC-209rce; 2H-indole-2,3-dione; EC 202-077-8; WLN: T56 BMVVJ; DSSTox_CID_18694; DSSTox_RID_79385; 3-Hydroxy-2H-indol-2-one; DSSTox_GSID_38694; SCHEMBL34016; 5-21-10-00221 (Beilstein Handbook Reference); 84788-92-1; KSC487A3D; MLS001066355; EBD271; DTXSID3038694; 2,3-Dihydro-indole-2,3-dione; BDBM11022; CTK3I7031; KS-00000DIU; NSC9262; HMS2267D18; S00335a; BCP15996; HY-Y0265; NSC-9262; ZINC2047514; 2,3-dihydro-1H-indol-2,3-dione; Tox21_202876; ANW-39708; BBL002302; s4717; SBB009100; STK387523; AKOS000119125; 2,3-Indolinedione; Indole-2,3-dione; CS-W020128; DB02095; LS21014; MCULE-2273580482; RTR-028840; CAS-91-56-5; TRA-0176250; NCGC00246983-01; NCGC00260422-01; AC-10666; AK-29599; AS-10908; BR-29599; LS-83004; SC-18090; SMR000471835; SY005277; AB1002676; DB-061345; ST2413137; TR-028840; AM20050218; FT-0627212; FT-0728767; I0080; ST50213409; AZ0001-0080; C11129; I-7800; I-7801; M-6110; A843979; Q421348; Z57127903; F9995-1662; Indole-2,3-dione; 2,3-Indolinedione; 1H-Indole-2,3-dione; Isatin, for spectrophotometric det. of proline and thiophene, >=99.0%; InChI=1/C8H5NO2/c10-7-5-3-1-2-4-6(5)9-8(7)11/h1-4H,(H,9,10,11; Indoline-2,3-dione; 2,3-Dioxo-2,3-dihydroindole; Isatic acid lactam; Isotin; Tribulin; 5-21-10-00221 (Beilstein Handbook Reference)
Isatoic anhydride 2H-3,1-Benzoxazine-2,4(1H)-dione; Isatoic anhydride; 118-48-9; 1H-Benzo[d][1,3]oxazine-2,4-dione; 2H-3,1-Benzoxazine-2,4(1H)-dione; 4H-3,1-Benzoxazine-2,4(1H)-dione; ISATOIC ACID ANHYDRIDE; 1H-3,1-benzoxazine-2,4-dione; Isato acid anhydride; N-Carboxyanthranilic anhydride; UNII-R8TFA74Y4U; HSDB 5017; 3,1-Benzoxazine-2,4(1H)-dione; Anthranilic acid, N-carboxy-, cyclic anhydride; EINECS 204-255-0; NSC 104662; Benzoic acid, 2-(carboxyamino)-, cyclic anhydride; BRN 0136786; R8TFA74Y4U; AI3-24983; CHEMBL346059; 2,4-dihydro-1H-3,1-benzoxazine-2,4-dione; TXJUTRJFNRYTHH-UHFFFAOYSA-N; Isatoic anhydride, 98%; DSSTox_CID_6955; 2H-3,4(1H)-dione; DSSTox_RID_78267; DSSTox_GSID_26955; Anthranilic acid, cyclic anhydride; benzo[d]1,3-oxazine-2,4-dione; CAS-118-48-9; MFCD00006700; PubChem13599; ACMC-1BVLV; Anthranilic acid N-carboxylic acid anhydride; Isatoic anhydride, 96%; EC 204-255-0; NCIOpen2_002029; SCHEMBL16251; ISATOIC ACID,ANHYDRIDE; 4-27-00-03330 (Beilstein Handbook Reference); Isatoic anhydride treated BSA; KSC179I0L; DTXSID6026955; CTK0H9405; KS-00000GFQ; 2,4-dioxo-1H-3,1-benzoxazine; HMS1607F14; 1H-[3,1]benzoxazine-2,4-dione; CS-M0780; NSC29555; ZINC8739076; Tox21_201325; Tox21_303058; 3,1-Benzoxazin-2,4-(1H)-dione; ANW-17139; BBL009904; BDBM50201570; NSC-29555; NSC104662; SBB003928; STK711078; 1h-benzo[d][1,3]oxazine-2,4dione; 2H-3,1-benzoxazine-2,4(1H)dione; 1h-benz(d)(1,3)oxazine-2,4-dione; AKOS000120179; 1H-benzo[d][1,3]oxazin-2,4-dione; AC-3291; DB11593; FS-3311; MCULE-9285695361; NSC-104662; 2H-3,1-benzoxazine-2,4-(1H)-dione; NCGC00164009-01; NCGC00164009-02; NCGC00257195-01; NCGC00258877-01; AK-54762; BP-10896; LS-41757; SC-19046; U260; 1,2-dihydro-3,1-benzoxazine-2,4-dione; AB1000156; DB-041408; FT-0627312; I0081; ST50330601; 2,4-dioxo-1,2-dihydro-4h-3,1-benzoxazine; AZ0001-0075; Isatoic anhydride treated bovine serum albumin; Isatoic anhydride, technical, >=94% (HPLC); M-7243; 118I489; A803947; AE-641/30105041; Q-103228; Q11286492; F0036-0953; Z1245636373; Isatoic Anhydride; Anthranilic acid N-carboxylic acid anhydride; InChI=1/C8H5NO3/c10-7-5-3-1-2-4-6(5)9-8(11)12-7/h1-4H,(H,9,11; Isatoic acid anhydride; 4-27-00-03330 (Beilstein Handbook Reference)
Isavuconazole 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; Isavuconazole; 241479-67-4; isavuconazol; BAL 4815; BAL-4815; UNII-60UTO373KE; Isavuconazole [INN]; Isavuconazole(BAL-4815; RO-0094815); 60UTO373KE; RO-0094815; CHEBI:85979; Isavuconazole (INN); 1286730-05-9; 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile; 4-[2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile; Bal4815; isavuconazolum; RO 0094815; BAL-8557(pro-drug); SCHEMBL939038; CHEMBL409153; DTXSID2058251; ASP9766; DDFOUSQFMYRUQK-RCDICMHDSA-N; 4-(2-((2R,3R)-Rel-3-(2,5-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile; BCP07587; EX-A1785; KS-00000T6L; ZINC1485935; 3748AH; s3722; AKOS027250772; API0013809; CS-3492; DB11633; SB16703; NCGC00390646-01; 4-[2-[(1R,2R)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]thiazol-4-yl]benzonitrile; AS-30128; HY-14273; SC-98350; BAL-4815; RO-0094815; FT-0670421; Isavuconazole; BAL-4815; RO-0094815; D10750; J-015363; Q6079042; BAL-4815; BAL4815; BAL 4815; RO-0094815; RO0094815; RO 0094815; (2R,3R)-3-[4-(4-cyanophenyl)thiazol-2-yl]-1-(1H-1,2,4-triazol-1-yl)-2-(2,5-difluorophenyl)-butan-2-ol; 4-(2-((2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl)thiazol-4-yl)benzonitrile; 4-{2-[(1R,2R)-2-(2,5-Difluoro-phenyl)-2-hydroxy-1-methyl -3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl}-benzonitrile; 4-{2-[(1R,2R)-2-(2,5-Difluoro-phenyl)-2-hydroxy-1-methyl-3-[1,2,4]triazol-1-yl-propyl]-thiazol-4-yl }-benzonitrile; 4-{2-[(2R,3R)-3-(2,5-difluorophenyl)-3-hydroxy-4-(1H-1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl}benzonitrile; Benzonitrile, 4-[2-[(1R,2R)-2-(2,5-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]-; Isavuconazole; UNII-60UTO373KE
Isocaproic acid 4-Methylpentanoic acid; Isocaproic acid; 4-02-00-00944 (Beilstein Handbook Reference)
Isoconazole 1-[2-(2,4-Dichlorophenyl)-2-[(2,6-dichlorophenyl)methoxy]ethyl]-1H-imidazole; Isoconazole; 1-(2-(2,4-Dichlorophenyl)-2-((2,6-dichlorophenyl)methoxy)ethyl)1H-imidazole
Isoflurane 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; isoflurane; 26675-46-7; 1-Chloro-2,2,2-trifluoroethyl difluoromethyl ether; Forane; Forene; Aerrane; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; Isoflurano; IsoFlo; Isofluranum; Compound 469; Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-; Isofluranum [INN-Latin]; R-E 235dal; AErrane (Veterinary); Isoflurano [INN-Spanish]; CCRIS 3043; Ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl; Isoflurane [Anaesthetics, volatile]; EINECS 247-897-7; BRN 1852087; CHEBI:6015; PIWKPBJCKXDKJR-UHFFFAOYSA-N; 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane; NCGC00181037-01; DSSTox_CID_752; DSSTox_RID_75769; 1-Chloro-2,2,2-trifluoroethyldifluoromethylether; DSSTox_GSID_20752; W-107162; UNII-CYS9AKD70P; Terrell; CAS-26675-46-7; Forane (TN); Isoflurane [USAN:INN:BAN:JAN]; 1-(difluoromethoxy)-1-chloro-2,2,2-trifluoroethane; CYS9AKD70P; HSDB 8057; MFCD00066609; Isoflurane [USAN:USP:INN:BAN:JAN]; Compd 469; Isoflurane, AldrichCPR; ACMC-209gsn; COMPOUND-469; SCHEMBL1532; CHEMBL1256; KSC497A6T; GTPL2505; Isoflurane (JP17/USP/INN); DTXSID3020752; CTK3J7069; BDBM217353; ZX-AP003878; Tox21_112685; Tox21_200831; ANW-26037; BBL100111; FCH917580; PC2045; SBB090213; STL454337; AKOS006228574; API0000986; DB00753; KS-5166; LS-7462; MCULE-2586244040; RTR-012058; KS-0000055Z; NCGC00181037-02; NCGC00258385-01; CC-04326; SC-17848; AB0008547; AB1010897; AC-154802; DB-046999; TR-012058; TR-031793; CS-0017450; FT-0627416; ST51041445; 1854-EP2272848A1; 1854-EP2275420A1; 1854-EP2280008A2; 1854-EP2287167A1; 1854-EP2289893A1; 1854-EP2298767A1; C-5056; C07518; D00545; EN300-123043; A818554; C-07277; Q413918; SR-01000944965; difluoromethyl 1-chloro-2,2,2-trifluoroethyl ether; SR-01000944965-1; 1-Chloro-1-(difluoromethoxy)-2,2,2-trifluoroethane; 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane; Ethane, 1-chloro-1-(difluoromethoxy)-2,2,2-trifluoro-; 2-[bis(fluoranyl)methoxy]-2-chloranyl-1,1,1-tris(fluoranyl)ethane; 2-Chloro-2-(difluoromethoxy)-1,1,1-trifluoroethane; Isoflurane; Isoflurane; R-E 235dal
Isoniazid 4-Pyridine carboxylic acid, Hydrazide; Isoniazid; L 1945
Isoprenaline 4-[1-Hydroxy-2-[(1-methylethyl)amino]ethyl]-1,2-benzenediol; Isoproterenol; 3-13-00-02387 (Beilstein Handbook Reference)
Isoquinoline ISOQUINOLINE; 119-65-3; 2-Azanaphthalene; 2-Benzazine; Benzo[c]pyridine; Isochinolin; Leucoline; beta-Quinoline; Benzo(c)pyridine; 2-Benzanine; 3,4-Benzopyridine; .beta.-Quinoline; Isochinolin [Czech]; NSC 3395; UNII-JGX76Y85M6; FEMA No. 2978; CCRIS 5752; Isoquinoline, 97%; EINECS 204-341-8; AI3-10035; JGX76Y85M6; CHEBI:16092; AWJUIBRHMBBTKR-UHFFFAOYSA-N; MFCD00006898; ISQ; isoquinolin; beta -quinoline; PubChem7536; Isoquinoline-5,8-D2; ACMC-1C9TZ; EC 204-341-8; SCHEMBL9654; DSSTox_CID_27644; DSSTox_RID_82471; DSSTox_GSID_47644; WLN: T66 CNJ; KSC176K7F; CHEMBL12315; SCHEMBL4543153; SCHEMBL6506458; SCHEMBL8569035; DTXSID2047644; BDBM60921; CTK0H6572; FEMA 2978; Isoquinoline, analytical standard; NSC3395; ZINC896098; BCP23537; BCP27363; NSC-3395; Tox21_302503; ANW-17357; BBL011362; MFCD31699977; SBB060380; STL146455; AKOS000119148; CM14380; CS-W013448; DB04329; EBD2220092; LS-2875; MCULE-5359867154; MP-2115; PS-5337; RTX-012412; RTE3_000001; TRA-0202111; Isoquinoline, technical grade, 90-92%; NCGC00188120-01; NCGC00256872-01; AK105903; CAS-119-65-3; I900; SC-46258; SY246282; 8-(1,4-diazepan-1-ylsulfonyl)isoquinoline; AB1007333; DB-003694; ST2413170; TC-106102; FT-0627506; I0182; ST51046570; PK04_181276; 5731-EP2268617A1; 5731-EP2269978A2; 5731-EP2269985A2; 5731-EP2269991A2; 5731-EP2270004A1; 5731-EP2270010A1; 5731-EP2270505A1; 5731-EP2272517A1; 5731-EP2272537A2; 5731-EP2272813A2; 5731-EP2272828A1; 5731-EP2272832A1; 5731-EP2272843A1; 5731-EP2272972A1; 5731-EP2272973A1; 5731-EP2275395A2; 5731-EP2275401A1; 5731-EP2275411A2; 5731-EP2275412A1; 5731-EP2277858A1; 5731-EP2277872A1; 5731-EP2280000A1; 5731-EP2281563A1; 5731-EP2281815A1; 5731-EP2281817A1; 5731-EP2281818A1; 5731-EP2284150A2; 5731-EP2284151A2; 5731-EP2284152A2; 5731-EP2284153A2; 5731-EP2284155A2; 5731-EP2284156A2; 5731-EP2284157A1; 5731-EP2284159A1; 5731-EP2284164A2; 5731-EP2284174A1; 5731-EP2284920A1; 5731-EP2285800A1; 5731-EP2287140A2; 5731-EP2287148A2; 5731-EP2287150A2; 5731-EP2287165A2; 5731-EP2287166A2; 5731-EP2289871A1; 5731-EP2289890A1; 5731-EP2289894A2; 5731-EP2292586A2; 5731-EP2292590A2; 5731-EP2292592A1; 5731-EP2292593A2; 5731-EP2292611A1; 5731-EP2292620A2; 5731-EP2292630A1; 5731-EP2295419A2; 5731-EP2295429A1; 5731-EP2295432A1; 5731-EP2295433A2; 5731-EP2295439A1; 5731-EP2298732A1; 5731-EP2298750A1; 5731-EP2298755A1; 5731-EP2298761A1; 5731-EP2298767A1; 5731-EP2298770A1; 5731-EP2301536A1; 5731-EP2301538A1; 5731-EP2301912A2; 5731-EP2301913A1; 5731-EP2301914A1; 5731-EP2301916A2; 5731-EP2301918A1; 5731-EP2301923A1; 5731-EP2301937A1; 5731-EP2303845A2; 5731-EP2305219A1; 5731-EP2305250A1; 5731-EP2305257A1; 5731-EP2305260A1; 5731-EP2305637A2; 5731-EP2305640A2; 5731-EP2305648A1; 5731-EP2305695A2; 5731-EP2305696A2; 5731-EP2305697A2; 5731-EP2305698A2; 5731-EP2308510A1; 5731-EP2308562A2; 5731-EP2308832A1; 5731-EP2308840A1; 5731-EP2308848A1; 5731-EP2308849A1; 5731-EP2308850A1; 5731-EP2308863A1; 5731-EP2308873A1; 5731-EP2308874A1; 5731-EP2308926A1; 5731-EP2309564A1; 5731-EP2311455A1; 5731-EP2311796A1; 5731-EP2311797A1; 5731-EP2311798A1; 5731-EP2311799A1; 5731-EP2311824A1; 5731-EP2311825A1; 5731-EP2311826A2; 5731-EP2311842A2; 5731-EP2314295A1; 5731-EP2314575A1; 5731-EP2314587A1; 5731-EP2316452A1; 5731-EP2316459A1; 5731-EP2316470A2; 5731-EP2316832A1; 5731-EP2316833A1; 5731-EP2316905A1; 5731-EP2316906A2; 5731-EP2371811A2; 5731-EP2371831A1; 5731-EP2372804A1; 5731-EP2378585A1; C06323; A804333; Q412316; W-108502; F0001-0310; InChI=1/C9H7N/c1-2-4-9-7-10-6-5-8(9)3-1/h1-7; 2241982-85-2; AI3-10035
Isotretinoin 13-cis-Retinoic acid; Isotretinoin; 4-09-00-02388 (Beilstein Handbook Reference)
Isovanillic acid 3-Hydroxy-4-methoxybenzoic acid; Isovanillic acid; 4-10-00-01460 (Beilstein Handbook Reference)
Josamycin josamycin; Leucomycin A3; Turimycin A5; Kitasamycin A3; Josamycine; Antibiotic yl-704 A3; JosamiciJosamycinum; Josamycine [INN-French]; Josamycinum [INN-Latin]; Josamicina [INN-Spanish]; 16846-24-5; Yl-704 A3; Leucomycin V, 3-acetate 4B-(3-methylbutanoate); UNII-HV13HFS217; EN-141; Josacine; EINECS 240-871-6; Leucomycin V 3-acetate 4b-(3-methylbutanoate); Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate); HV13HFS217; Leucomycin V, 3-acetate 4(sup beta)-(3-methylbutanoate); JM; CHEBI:31739; ST075007; Stereoisomer of 4-(acetyloxy)-6-((3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-4-O-(3-methyl-1-oxobutyl)-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranosyl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-diene-7-acetaldehyde; Stereoisomer of 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4'-acetate 4''-isovalerate; EN 141; Stereoisomer of 7-(formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4'-acetate 4'-isovalerate; Josamycin [USAN:INN:JAN]; CCRIS 8511; NSC122223; Josamycin [USAN:INN:BAN:JAN]; Josamycin (TN); SCHEMBL132829; Leucomycin V 3-acetate 4(beta)-(3-methylbutanoate); CHEMBL224436; Josamycin (JP17/USAN/INN); Josamycin, >=98.0% (UV); XJSFLOJWULLJQS-NGVXBBESSA-N; 11033-18-4; HY-B1920; 8158AH; s4421; ZINC96006021; DB01321; LS-87883; LS-185083; TR-007321; CS-0013975; C12662; D01235; leucomycin V 3-acetate 4(B)-(3-methylbutanoate); leucomycin V 3-acetate 4beta-(3-methylbutanoate); Q423369; SR-01000883731; SR-01000883731-1; Josamycin, European Pharmacopoeia (EP) Reference Standard; UNII-G986N7X02W component XJSFLOJWULLJQS-NGVXBBESSA-N; hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimethyloxan-3-yl] 3-methylbutanoate; Josamycin for peak identification, European Pharmacopoeia (EP) Reference Standard; (2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-(acetyloxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate; [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetoxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyl-tetrahydropyran-3-yl]oxy-4-hydroxy-2,4-dimethyl-tetrahydropyran-3-yl] 3-methylbutanoate; [(2S,3S,4R,6S)-6-[(2R,3S,4R,5R,6S)-6-[[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-acetyloxy-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy]-4-(dimethylamino)-5-; 56689-45-3; 6-{6-[(1S,13S,2R,3R,7R,14R,16R)-3-acetyloxy-13-hydroxy-2-methoxy-7,14-dimethyl -5-oxo-16-(2-oxoethyl)-6-oxacyclohexadeca-9,11-dienyloxy](3S,2R,4R,5R,6R)-4-(d imethylamino)-5-hydroxy-2-methyl(2H-3,4,5,; 6-{6-[3-Acetyloxy-13-hydroxy-2-methoxy-7,14-dimethyl-6-oxa-5-oxo-16-(2-oxoethyl)cyclohexadeca-9,11-dienyloxy]-4-(dimethylamino)-5-hydroxy-2-methylperhydro-2H-pyran-3-yloxy}-4-hydroxy-2,4-dimethylperhydro-2H-pyran-3-yl 3-methylbutanoate; 6-tetrahydropyran-3-yloxy)}(2S,3S,4R ,6R)-4-hydroxy-2,4-dimethyl-2H-3,4,5,6-tetrahydropyran-3-yl 3-methylbutanoate; Josamycin 10 microg/mL in Acetonitrile. Short expiry date due to chemical nature of component(s); josamycin; 16846-24-5; DB-043741; FT-0630434; 6-[(6-{[4-(acetyloxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl)oxy]-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate; josamycin; 16846-24-5; AC1NR4PM; NCGC00016725-01; 4-(acetyloxy)-6-((3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-4-O-(3-methyl-1-oxobutyl)-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranosyl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-diene-7-acetaldehyde; CAS-16846-24-5; DSSTox_CID_3183; DSSTox_RID_76910; DSSTox_GSID_23183; SCHEMBL132828; CHEMBL2361089; DTXSID8023183; Tox21_110583; josamycin; 16846-24-5; Prestwick_517; Prestwick2_000154; CHEMBL329011; HMS1568O10; josamycin; 16846-24-5; CTK8F0433; josamycin; Josacine; EN 141; NSC122223; CHEMBL1995525; 16846-24-5; NSC-116068; NSC-122223; josamycin; 11033-18-4; 16846-24-5; josamycin; 16846-24-5; SMP2_000131; josamycin; 16846-24-5; josamycin; 16846-24-5; josamycin; antibioticyl-704a3; 16846-24-5; BCP23612; josamycin; 16846-24-5; Antibiotic yl-704 A3
Kaempferol 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; kaempferol; 520-18-3; Kempferol; Kaempherol; Robigenin; Rhamnolutein; Populnetin; Trifolitin; Pelargidenolon; Rhamnolutin; Swartziol; 3,4',5,7-Tetrahydroxyflavone; Kampherol; Indigo Yellow; Campherol; Kampferol; Kaemferol; Nimbecetin; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Flavone, 3,4',5,7-tetrahydroxy-; NSC 407289; NSC 656277; UNII-731P2LE49E; EINECS 208-287-6; CHEMBL150; BRN 0304401; AI3-36096; CHEBI:28499; IYRMWMYZSQPJKC-UHFFFAOYSA-N; 731P2LE49E; MFCD00016938; NSC656277; NSC-407289; NSC-656277; CAS-520-18-3; DSSTox_CID_768; DSSTox_RID_75781; DSSTox_GSID_20768; Q-100584; SMR000112585; Pelargidenon; Kampcetin; 3,5,7,4'-Tetrahydroxyflavone; HSDB 7703; 4det; Kaempferol,(S); Kaempferol, 97%; 3,4′ ,5,7-Tetrahydroxyflavone; 5,4'-Trihydroxyflavonol; Prestwick0_001098; Prestwick1_001098; Prestwick2_001098; Prestwick3_001098; 3,5,7-Tetrahydroxyflavone; 4',5,7-trihydroxyflavonol; BIDD:PXR0073; Oprea1_650954; SCHEMBL18817; BSPBio_001176; 5-18-05-00251 (Beilstein Handbook Reference); MLS000697730; MLS001055391; MLS001074884; MLS006010737; BIDD:ER0134; SPBio_003058; 3,4,5,7-Tetrahydroxyflavone; Kaempferol, analytical standard; BDBM7462; BPBio1_001294; MEGxp0_001283; DTXSID7020768; Flavone,4',5,7-tetrahydroxy-; ACon1_001867; cid_5280863; CHEBI: 28499; HMS1571K18; HMS2098K18; HMS2267I09; HMS3414C03; HMS3656M03; HMS3678C03; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1- benzopyran-4-one; Kaempferol, >=97.0% (HPLC); TNP00039; ZINC3869768; Tox21_201165; Tox21_303363; AC-544; CK0011; GP7425; HSCI1_000027; LMPK12110003; LS-176; NSC407289; s2314; SBB066091; AKOS015895240; Kaempferol, >=90% (HPLC), powder; CCG-202823; CS-1273; DB01852; GS-3570; MCULE-8965218413; NCGC00016480-01; NCGC00016480-02; NCGC00016480-03; NCGC00016480-04; NCGC00016480-05; NCGC00016480-06; NCGC00016480-07; NCGC00016480-09; NCGC00091036-01; NCGC00091036-02; NCGC00164322-01; NCGC00179275-01; NCGC00179275-02; NCGC00257464-01; NCGC00258717-01; AK168074; CC-29746; HY-14590; SC-17291; ST030560; SY023424; AB0010534; TR-018501; AB00514046; FT-0614420; K0018; N1719; SW197199-2; W1682; 3,4',5,7-tetrahydroxy-Flavone (7CI,8CI); A10495; C05903; J10449; S00111; W-2776; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); 520K183; A828886; C-18018; Q393336; SR-01000765646; Kaempferol, primary pharmaceutical reference standard; SR-01000765646-3; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-chromen-4-one; BRD-K12807006-001-05-2; BRD-K12807006-001-10-2; 2-(4-hydroxyphenyl)-3,5,7-tris(oxidanyl)chromen-4-one; A91A6666-86C8-4B33-B3EF-F74CD3CD7F47; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Kaempferol, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Kaempferol; C.I. 75640
Kanamycin kanamycin; KANAMYCIN A; Kanamycin Base; 59-01-8; Kanamycin sulfate; Kanamycine; Kanamicina [Italian]; KM (the Antibiotic); Kanamycin [INN:BAN]; Kanamycine [INN-French]; Kanamycinum [INN-Latin]; UNII-EQK9Q303C5; CHEBI:17630; HSDB 3107; C18H36N4O11; EINECS 200-411-7; BRN 0061647; 4,6-Diamino-2-hydroxy-1,3-cyclohexane 3,6'diamino-3,6'-dideoxydi-alpha-D-glucoside; EQK9Q303C5; KAN; 8063-07-8; Kanamycinum; KanamiciGlucopyranoside, 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-, D-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1,4))-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-2-deoxy-; 4,6-diamino-2-hydroxy-1,3-cyclohexylene 3,6'-diamino-3,6'-dideoxydi-D-glucopyranoside; (1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; Kanamycin,(S); Liposomal Kanamycin; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2-hydroxy-cyclohexoxy]tetrahydropyran-3,4,5-triol; Prestwick3_000394; Kantrex (1:1 sulfate); Klebcil (1:1 sulfate); SCHEMBL2735; CHEMBL1384; BSPBio_000607; DivK1c_000024; BPBio1_000669; DTXSID3023184; CTK8G0428; KBio1_000024; NINDS_000024; SBUJHOSQTJFQJX-NOAMYHISSA-N; ZINC8214590; BDBM50031282; KM0269; AKOS025293505; API0003071; DB01172; IDI1_000024; SMP2_000007; NCGC00179506-01; AS-14003; K434; LS-146900; AB00513827; C01822; BRD-K08327065-065-01-9; Q27094615; Kanamycin sulfate, Antibiotic for Culture Media Use Only; UNII-RUC37XUP2P component SBUJHOSQTJFQJX-NOAMYHISSA-N; (1S,2R,3R,4S,6R)-4,6-diamino-3-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-((1R,2R,3S,4R,6S)-4,6-diamino-3-((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2-hydroxycyclohexyloxy)tetrahydro-2H-pyran-3,4,5-triol; (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-3-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}oxane-3,4,5-triol; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1.fwdarw.4))-2-deoxy-; Kanamycin solution from Streptomyces kanamyceticus, 10 mg/mL in 0.9% NaCl, sterile-filtered, BioReagent, suitable for cell culture; Kanamycin solution from Streptomyces kanamyceticus, 50 mg/mL in 0.9% NaCl, BioReagent, liquid, sterile-filtered, suitable for cell culture; O-3-Amino-3-deoxy-.alpha.-D-glucopyranosyl-(1->6)-O-[6-amino-6-deoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy-D-streptamine; O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1->6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1->4))-2-deoxy-D-streptamine; EINECS 232-512-7
Kanamycin sulphate Cantrex
Ketanserin 3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; Ketanserin; 74050-98-9; Ketanserin tartrate; Ketanserinum; Ketaserin; KetanseriKetanserine; Ketanserine [INN-French]; Ketanserinum [INN-Latin]; 3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)ethyl)quinazoline-2,4(1H,3H)-dione; Ketanserina [INN-Spanish]; R-41468; UNII-97F9DE4CT4; R 41468; [3H]-Ketanserin; R 41,468; R-41,468; C22H22FN3O3; CHEMBL51; EINECS 277-680-2; 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 97F9DE4CT4; CHEBI:6123; FPCCSQOGAWCVBH-UHFFFAOYSA-N; 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione; [3H]ketanserin; 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(p-Fluorobenzoyl)piperidino)ethyl)-2,4-(1H,3H)-quinazolinedione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione; NCGC00021146-06; DSSTox_CID_3188; 2,4(1H,3H)-Quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-; DSSTox_RID_76913; DSSTox_GSID_23188; W-104435; Perketal; Serefrex; Sufrexal; Taseron; 83846-83-7; Vulketan Gel; 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-{2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl}-2,4(1H,3H)-quinazolinedione; 2,4(1H,3H)-Quinazolinedione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-; 2,4(1H,3H)-Quinazolinedione,3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-; Ketanserin [USAN:BAN:INN]; CAS-74050-98-9; Ketanserin (USAN/INN); Kentanserin; Ketanserin [USAN:INN:BAN]; R-41-468; 3-[2-[4-(p-Fluorobenzoyl)piperidino]ethyl]-2,4-(1H,3H)-quinazolinedione; Tocris-0908; Spectrum2_001713; Ketanserin (Vulketan Gel); Biomol-NT_000096; GTPL88; R 41468; Vulketan Gel; R41468; R41,468; SCHEMBL34294; GTPL197; MLS006010073; SPECTRUM1505346; SPBio_001726; BPBio1_001356; DTXSID3023188; BDBM21395; CTK8G0431; KS-00000XLH; AOB5639; HMS1923O11; HMS2090H18; HMS2094I03; HMS3655H14; Pharmakon1600-01505346; ZINC537877; Tox21_110865; CCG-39512; NSC758959; PDSP1_000639; PDSP2_000634; s2232; AKOS015895130; Tox21_110865_1; AC-2024; API0003079; CS-6055; DB12465; GS-3601; NSC-758959; SDCCGSBI-0051158.P004; (+)-3-[2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; 3-(2-(4-(4-Fluorobenzoyl)piperidin-1-yl)-ethyl)quinazoline-2,4(1H,3H)-dione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione; NCGC00021146-01; NCGC00021146-02; NCGC00021146-03; NCGC00021146-04; NCGC00021146-05; NCGC00021146-07; NCGC00021146-08; NCGC00021146-09; NCGC00021146-12; NCGC00024865-01; NCGC00024865-02; NCGC00024865-03; NCGC00024865-04; NCGC00024865-05; CC-29757; HY-10562; K261; SC-17248; SMR001550601; SBI-0051158.P003; AB0014126; AB2000544; AX8034794; DB-055834; LS-140148; FT-0630827; FT-0653664; K0051; SW196882-3; C07464; D02363; 050K989; 191037-EP2275420A1; 191037-EP2280008A2; A838000; C-21630; L000764; Q415997; R41 468; BRD-K49671696-001-02-1; BRD-K49671696-347-02-8; F2173-1039; KETANSERIN, Ketanserin tartrate hydrate, KETANSERIN TARTRATE; 3-(2-[4-(4-Fluorobenzoyl)-1-piperidinyl]ethyl)-2,4(1H,3H)-quinazolinedione #; 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-ethyl]-2,4-[1H, 3H]-quinazolinedione; 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4-(1H,3H)-quinazolinedione; 3-[2-[4-(4-fluorophenyl)carbonylpiperidin-1-yl]ethyl]-1H-quinazoline-2,4-dione; 3-[2-[4-[(4-fluorophenyl)-oxomethyl]-1-piperidinyl]ethyl]-1H-quinazoline-2,4-dione; 3-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-1h-quinazoline-2,4-dione; 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione; 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione; Ketanserin; EINECS 277-680-2
Ketoprofen 3-Benzoyl-alpha-methylbenzeneacetic acid; Ketoprofen; 19583 RP
Kojic acid 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; kojic acid; 501-30-4; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one; 5-Hydroxy-2-(hydroxymethyl)-4-pyrone; 5-Hydroxy-2-hydroxymethyl-4-pyrone; 4H-PYRAN-4-ONE, 5-HYDROXY-2-(HYDROXYMETHYL)-; 5-hydroxy-2-(hydroxymethyl)pyran-4-one; acido kojico; 2-Hydroxymethyl-5-hydroxy-gamma-pyrone; 2-(Hydroxymethyl)-5-hydroxy-4H-pyran-4-one; UNII-6K23F1TT52; CCRIS 4131; 5-Hydroxy-2-hydroxymethyl-4H-4-pyranone; NSC 1942; EINECS 207-922-4; MFCD00006580; BRN 0120895; 5-Hydroxy-2-hydroxymethyl-4H-pyran-4-one; AI3-02549; Pyran-4-one, 5-hydroxy-2-(hydroxymethyl); CHEMBL287556; CHEBI:43572; NSC1942; BEJNERDRQOWKJM-UHFFFAOYSA-N; 6K23F1TT52; Kojic acid, 99%; 5-Hydroxy-2-hydroxymethyl-pyran-4-one; NCGC00017325-03; NCGC00017325-06; DSSTox_CID_20236; DSSTox_RID_79455; DSSTox_GSID_40236; CAS-501-30-4; Kojisaeure; HSDB 7664; Kojic Acid Solution; Spectrum_000191; Spectrum2_001828; Spectrum3_001704; Spectrum4_000571; Spectrum5_001085; Natural Kojic Acid Powder; Kojic Acid Dipalmitate 5kg; Oprea1_038773; SCHEMBL36895; BSPBio_003288; KBioGR_001002; KBioSS_000671; 5-18-02-00516 (Beilstein Handbook Reference); BIDD:ER0501; DivK1c_000923; SPBio_001875; Kojic acid, analytical standard; MEGxm0_000388; WLN: T6O DVJ B1Q EQ; DTXSID2040236; ACon1_000622; BEJNERDRQOWKJM-UHFFFAOYSA-; HMS502O05; KBio1_000923; KBio2_000671; KBio2_003239; KBio2_005807; KBio3_002508; KS-00000GGK; NINDS_000923; HMS3604L04; KUC106760N; EBD70941; NSC-1942; TNP00261; 2-Hydroxymethyl-5-hydroxy-?-pyrone; 2-Hydroxymethyl-5-Hydroxy-G-Pyrone; Tox21_110814; Tox21_113449; ANW-46611; BBL010645; BDBM50031467; CCG-38458; s5174; SBB005397; STK801688; ZINC13831818; AKOS000120649; Tox21_110814_1; 5-Hydroxy-2-hydroxymethyl-I(3)-pyron; DB01759; HY-W050154; MCULE-1079267668; RTR-036891; IDI1_000923; SMP1_000171; NCGC00017325-01; NCGC00017325-02; NCGC00017325-04; NCGC00017325-05; NCGC00142361-01; NCGC00168903-01; NCGC00168903-02; NCGC00181145-01; AC-11658; AK-84878; AS-11648; H802; Kojic acid, purum, >=98.0% (HPLC); KSC-11-228-2; SC-81009; ST019399; 2-HYDROXYMETHYL-5-HYDROXY-4-PYRONE; 2-Hydroxymethyl-5-hydroxy-4H-pyran-4-one; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-; AB0010492; LS-127450; ST2412032; CS-0032701; FT-0081379; FT-0627581; K0010; K0012; 01K304; C14516; M-6079; Q416285; SR-01000945134; SR-01000945134-1; 5-Hydroxy-2-(hydroxymethyl)-4H-pyran-4-one Solution; C65A72E0-0E46-4AF4-AA68-178ECA2E5FCC; F0001-1307; Z381040328; InChI=1/C6H6O4/c7-2-4-1-5(8)6(9)3-10-4/h1,3,7,9H,2H2; 5-18-02-00516 (Beilstein Handbook Reference)
Kynurenic acid 4-Hydroxy-2-quinolinecarboxylic acid; Kynurenic acid; CCRIS 4428
L-Aspartic acid Aspartic acid; 4-04-00-02998 (Beilstein Handbook Reference)
L-Cysteic acid 3-Sulfo-L-alanine; L-Cysteic acid; 498-40-8; Cysteinesulfonic acid; L-Alanine, 3-sulfo-; 3-sulfo-L-alanine; (R)-2-Amino-3-sulfopropanoic acid; Cysteric acid; (2R)-2-amino-3-sulfopropanoic acid; Cysteic acid (VAN); Cysteinic acid; Cepteic acid; Cipteic acid; 3-Sulfoalanine; UNII-M6W2DJ6N5K; 2-Amino-3-sulfopropionic acid; Alanine, 3-sulfo-, L-; M6W2DJ6N5K; L-Cysteate; L-Alanine, 3-sulfo- (9CI); Alanine, 3-sulfo-, L- (8CI); alpha-amino-beta-sulfopropionic acid; Alanine, 3-sulfo-; L-Cysteic acid, 99%; Cysteic acid, L-; NSC 254030; C3H7NO5S; H-Cys(O)2-OH.H2O; (2R)-2-amino-3-sulfo-propanoic acid; EINECS 207-861-3; bmse000380; SCHEMBL44031; KSC179I1D; DTXSID7075424; CHEBI:17285; CTK0H9411; KS-00000GHF; XVOYSCVBGLVSOL-REOHCLBHSA-N; ZINC4228276; 7067AF; ANW-30856; AKOS006281833; AKOS015854116; (2R)-2-amino-3-sulfo-propionic acid; DB03661; RTR-031936; (2R)-2-azanyl-3-sulfo-propanoic acid; AK322574; DS-12037; OCS; ST079666; TR-031936; FT-0627746; C00506; Q29743881; UNII-A3OGP4C37W component XVOYSCVBGLVSOL-REOHCLBHSA-N; Cysteic acid, L-; Cepteic acid
L-Cysteinesulphinic acid 3-Sulfino-L-alanine; L-Cysteinesulfinic acid; 1115-65-7; 3-Sulfino-L-alanine; 3-sulfinoalanine; 3-sulphino-L-alanine; (2R)-2-amino-3-sulfinopropanoic acid; Cysteinesulfinic acid; L-cysteine sulphinic acid; L-Cysteinesulphinic Acid; L-Alanine, 3-sulfino-; L-Cysteine sulfinic acid; Cysteine sulfinic acid; Cysteine sulfinate; UNII-56X032NVQL; 56X032NVQL; CHEBI:16345; ADVPTQAUNPRNPO-REOHCLBHSA-N; 3-sulfinato-L-alaninate; S-sulfinocysteine; Sulfino-D-alanine; EINECS 214-228-5; S-cysteinesulfinic acid; Tocris-0216; L-CSA; Cysteinesulfinic acid, L-; Biomol-NT_000190; bmse000706; Alanine, 3-sulfino-, L-; C3H7NO4S.H2O; Lopac0_000263; SCHEMBL189097; BPBio1_001212; GTPL5447; CHEMBL1160508; CTK0H5128; DTXSID20862546; HMS3260F08; HMS3411A19; HMS3675A19; L-2-Amino-3-sulfinopropionic acid; Tox21_500263; ZINC19419008; AKOS006280503; CCG-204358; DB02153; LP00263; SDCCGSBI-0050251.P002; NCGC00024500-01; NCGC00024500-02; NCGC00024500-03; NCGC00024500-04; NCGC00024500-05; NCGC00260948-01; HY-100804; B6225; CS-0020450; EU-0100263; FT-0633338; C 4418; C00606; S-CYSTEINESULFINIC ACID; S-SULFINOCYSTEINE; SR-01000075758; SR-01000597398; Q2823252; SR-01000075758-1; SR-01000597398-1; FF909059-FA51-40A0-8973-9E4ECFB8C92A; UNII-UZY4HYK4ZX component ADVPTQAUNPRNPO-REOHCLBHSA-N; Cysteinesulfinic acid, L-; EINECS 214-228-5
L-Name N5-[Imino(nitroamino)methyl]-L-ornithine,Methyl ester; NG-Nitroarginine methyl ester; N(5)-(Imino(nitroamino)methyl)-L-ornithine methyl ester
L-Pyroglutamic acid 5-Oxo-L-Proline; L-Pyroglutamic acid; 98-79-3; Pyroglutamic acid; Pidolic acid; 5-oxo-L-proline; H-Pyr-OH; 5-OXOPROLINE; (2S)-5-oxopyrrolidine-2-carboxylic acid; (S)-5-Oxopyrrolidine-2-carboxylic Acid; L-5-Oxoproline; L-Proline, 5-oxo-; Pyroglutamate; Pyrrolidonecarboxylic acid; (S)-(-)-2-Pyrrolidone-5-carboxylic acid; GLUTIMIC ACID; Proline, 5-oxo-; 5-L-Oxoproline; (S)-PYROGLUTAMIC ACID; 5-Carboxy-2-pyrrolidinone; Pidolate; (-)-2-Pyrrolidone-5-carboxylic acid; 2-Pyrrolidinone-5-carboxylic acid; L-5-Carboxy-2-pyrrolidinone; L-GLUTIMINIC ACID; L-5-Oxo-2-pyrrolidinecarboxylic acid; 5-Pyrrolidone-2-carboxylic acid; 5-Pyrrolidinone-2-carboxylic acid; 2-L-Pyrrolidone-5-carboxylic acid; OXOPROLINE; AJIDEW A-100; GLUTIMINIC ACID; L-GLUTIMIC ACID; Pidolidone; (S)-5-Oxo-2-pyrrolidinecarboxylic acid; L-2-PYRROLIDONE-5-CARBOXYLIC ACID; L-5-Pyrrolidone-2-carboxylic acid; 2-Pyrrolidone-5-carboxylate; L-Glutamic acid gamma-lactam; NSC 143034; Pyr-OH; Acide pidolique [INN-French]; Acido pidolico [INN-Spanish]; Acidum pidolicum [INN-Latin]; L-Pyroglutamate; (5S)-2-Oxopyrrolidine-5-carboxylic acid; PYRROLIDINONECARBOXYLIC ACID; L-PYRROLIDONECARBOXYLIC ACID; 2-Oxopyrrolidine-5-carboxylic acid; NSC 9966; EINECS 202-700-3; L-PYRROLIDINONECARBOXYLIC ACID; PYRROLIDONE-5-CARBOXYLIC ACID; Proline, 5-oxo-, L-; 2-Benzothiazolesulfenic acid morpholide; pyroglu; CHEBI:18183; NSC9966; ODHCTXKNWHHXJC-VKHMYHEASA-N; MFCD00005272; (S)-2-Pyrrolidone-5-carboxylic acid; NCGC00160613-01; DSSTox_CID_26260; DSSTox_RID_81487; DSSTox_GSID_46260; 5-OXO-2-PYRROLIDINECARBOXYLIC ACID; Acide pidolique; oxo-proline; Acido pidolico; Acidum pidolicum; L-Pyroglutamicacid; CAS-98-79-3; pGlu-OH; SMR000857158; Pidolic acid [INN]; (S)-(-)-2-Pyrrolidone-5-carboxylic acid, 98%; Pidolic acid [INN:BAN]; Glutiminate; Glutimate; pGlu; L-Glutiminate; L-Glutimate; (S)-Pyroglutamate; (-)-Pyroglutamate; L-pyro-glutamic acid; PubChem8104; Pyrrolidinonecarboxylate; (L)-pyroglutamic acid; Ajidew A 100; L-Pyrrolidonecarboxylate; Oxopyrrolidinecarboxylate; (-)-Pyroglutamic acid; L-Glutamic Acid Lactam; L-Pyrrolidinonecarboxylate; Pyrrolidone-5-carboxylate; L-Glutamic acid g-lactam; Rec-PGA 273K; pyrrolidone car-boxylic acid; L-Pyroglutamic acid, 97%; Oxopyrrolidinecarboxylic acid; l-pyrrolidone carboxylic acid; SCHEMBL15790; (S)-(-)-pyroglutamic acid; L-Pyroglutamic acid, BioXtra; MLS001332421; MLS001332422; 2-Pyrrolidinone-5-carboxylate; 5-Pyrrolidinone-2-carboxylate; 2-L-Pyrrolidone-5-carboxylate; L-2-Pyrrolidone-5-carboxylate; CHEMBL397976; L-Glutamic acid .gamma.-lactam; PYROGLUTAMIC ACID, (L); DTXSID6046260; CTK7H2889; (S)-2-Pyrrolidone-5-carboxylate; L-5-Oxo-2-pyrrolidinecarboxylate; (-)-2-Pyrrolidone-5-carboxylate; HMS2231L11; HMS3264E20; Pharmakon1600-01506185; 2-Oxopyrrolidine-5(S)-carboxylate; ACT09037; CS-M0659; NSC-9966; NSC11742; STR02331; ZINC3598263; (S)-5-Oxo-2-pyrrolidinecarboxylate; Tox21_111936; ANW-52541; CCG-36432; NSC-11742; NSC760414; s5823; SBB004232; (5S)-2-Oxopyrrolidine-5-carboxylate; AKOS015855330; Tox21_111936_1; (2S)-5-pyrrolidone-2-carboxylic acid; (S)-(-)-g-Butyrolactam-g-carboxylate; (S)-5-oxopyrolidine-2-carboxylic acid; 2-Oxopyrrolidine-5(S)-carboxylic acid; AM83732; DB03088; EBD2198219; MCULE-4204877494; NE10392; NSC-760414; RTR-030362; (S)-(-)-2-Pyrrolidone-5-carboxylate; KS-0000050B; L-Pyroglutamic acid, >=99.0% (T); (5S)-2-xopyrrolidine-5-carboxylic acid; NCGC00160613-02; (S)-5-oxo-pyrrolidine-2-carboxylic acid; AC-15173; BP-12844; HY-76082; K772; R071; SC-07520; ST069342; (S)-(-)-g-Butyrolactam-g-carboxylic acid; AB0007851; AB1001577; DB-002779; LS-118965; TR-030362; FT-0605097; P0573; ST24020841; (S)-(-)-gamma-Butyrolactam-gamma-carboxylate; (S)?-?5-?Oxo-?2-?pyrrolidinecarboxylic acid; C01879; M03204; P-8490; AB00514366_07; (S)-(-)-gamma-Butyrolactam-gamma-carboxylic acid; 005P272; Q60998677; F8889-8712; Z1259273294; UNII-3QN0K2A6Q8 component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-4JDT453NWO component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-6603L01WUR component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-6VT1YZM21H component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-B4S8ET206U component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-K3Z4F929H6 component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-Q1M94GA18P component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-QSM06A70MD component ODHCTXKNWHHXJC-VKHMYHEASA-N; UNII-SZB83O1W42 component ODHCTXKNWHHXJC-VKHMYHEASA-N; Pidolic acid, European Pharmacopoeia (EP) Reference Standard; E478F48D-E369-43AE-8132-08D819242518; Pyroglutamic Acid, United States Pharmacopeia (USP) Reference Standard; 5-Oxo-L-proline; Acide pidolique [INN-French]
L-Serine L-serine; serine; 56-45-1; (S)-2-Amino-3-hydroxypropanoic acid; H-Ser-OH; (S)-Serine; beta-Hydroxyalanine; L-ser; (2S)-2-amino-3-hydroxypropanoic acid; L-Serin; L-(-)-Serine; Polyserine; Serine, L-; 2-Amino-3-hydroxypropionic acid; Poly-L-serine; Serinum [Latin]; Serina [Spanish]; Serine (VAN); L-3-Hydroxy-alanine; beta-Hydroxy-L-alanine; L-2-Amino-3-hydroxypropionic acid; Serine [USAN:INN]; SER (IUPAC abbrev); alpha-Amino-beta-hydroxypropionic acid; L-3-Hydroxy-2-aminopropionic acid; (-)-Serine; (S)-2-Amino-3-hydroxypropionic acid; HSDB 680; (S)-(-)-Serine; 2-Amino-3-hydroxypropanoic acid, (S)-; Propanoic acid, 2-amino-3-hydroxy-, (S)-; BRN 1721404; 3-Hydroxyalanine; ser; UNII-452VLY9402; CHEBI:17115; (S)-alpha-Amino-beta-hydroxypropionic acid; EINECS 200-274-3; MFCD00064224; NSC 118365; MTCFGRXMJLQNBG-REOHCLBHSA-N; Serine (L-Serine); 452VLY9402; (S)-2-amino-3-hydroxy-Propanoic acid; L-Serine, 99%; (S)-(+)-2-Amino-3-hydroxypropionic acid; serin; Serinum; Serene; Serina; .beta.-Hydroxyalanine; b-Hydroxy-L-alanine; polyserine, (DL)-isomer; Protein serine; rac-serine; Racemic serine; 2-amino-3-hydroxypropanoate; 2-Amino-3-hydroxypropionate; NSC-118365; 3h-l-serine; L-Serine; H-Ser; (S)-a-Amino-b-hydroxypropionic acid; Serine (USP); 3-hydroxy-L-Alanine; L-Serine,(S); L-Serine, homopolymer; PubChem10994; Tocris-0226; Tocris-0227; L-Serine (JP17); L-Alanine, 3-hydroxy-; Lopac-S-4250; (L)-SERINE; bmse000048; bmse000809; bmse000867; bmse000885; Epitope ID:150900; EC 200-274-3; SCHEMBL1775; GTPL726; 25821-52-7; 4-04-00-03118 (Beilstein Handbook Reference); KSC269O8R; CHEMBL11298; L-3-Hydroxy-2-aminopropionate; (S)-a-Amino-b-hydroxypropionate; CTK1G9788; (S)-b-Amino-3-hydroxypropionate; DTXSID60883230; (S)-2-Amino-3-hydroxypropanoate; Pharmakon1600-01301010; ZINC895034; (S)-2-amino-3-hydroxy-Propanoate; ACT08366; HY-N0650; L-2-Amino-3-hydroxypropanoic Acid; L-Serine, Vetec(TM), 98.5%; STR02557; (S)-beta-Amino-3-hydroxypropionate; l-2-Amino-3-hydroxy-propanoic acid; L-Serine, >=99.0% (NT); ANW-32514; BDBM50357212; NSC760115; (S)-b-Amino-3-hydroxypropionic acid; AKOS015854115; (S)-alpha-Amino-beta-hydroxypropionate; AC-1190; CS-W020136; DB00133; EBD2198140; MCULE-5604658333; NSC-760115; RTC-066532; VC30786; (S)-beta-Amino-3-hydroxypropionic acid; L-Serine, tested according to Ph.Eur.; (2S)-2-amino-3-hydroxypropanoic acid.; NCGC00015952-01; NCGC00024507-01; NCGC00024507-02; BP-13282; BR-73019; L-Serine, BioUltra, >=99.5% (NT); SC-09827; 2-Amino-3-hydroxypropanoic acid-, (S)-; AB0008559; AB1002443; DB-029983; LS-144975; Propanoic acid, 2-amino-3-hydroxy-, (S); ST2408299; TC-066532; AM20100375; FT-0627627; FT-0693445; S0035; S9353; L-Serine, ReagentPlus(R), >=99% (HPLC); L-Serine, Vetec(TM) reagent grade, >=99%; C00065; D00016; M-6047; 88848-EP2289892A1; 88848-EP2305825A1; 064S224; Q183290; SR-01000597708; .alpha.-Amino-.beta.-hydroxypropionic acid-, (S)-; SR-01000597708-1; L-Serine, certified reference material, TraceCERT(R); F1905-7047; Serine, European Pharmacopoeia (EP) Reference Standard; Z1270387256; 3AB40D3A-043A-488F-8361-D1BF309F842C; UNII-00PAR1C66F component MTCFGRXMJLQNBG-REOHCLBHSA-N; UNII-0O72R8RF8A component MTCFGRXMJLQNBG-REOHCLBHSA-N; L-Serine, United States Pharmacopeia (USP) Reference Standard; L-Serine, Pharmaceutical Secondary Standard; Certified Reference Material; L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%; L-Serine, PharmaGrade, Ajinomoto, EP, USP, JP, Manufactured under appropriate controls for use in pharma or biopharmaceutical production, suitable for cell culture; L-Serine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture; 2-Amino-3-hydroxypropionic acid; 4-04-00-03118 (Beilstein Handbook Reference)
L-Tyrosine L-tyrosine; tyrosine; 60-18-4; (S)-Tyrosine; p-Tyrosine; H-Tyr-OH; L-p-Tyrosine; 4-Hydroxy-L-phenylalanine; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; Tyrosinum [Latin]; Tyrosine (VAN); Tirosina [Spanish]; L-(-)-Tyrosine; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; L-Phenylalanine, 4-hydroxy-; beta-(p-Hydroxyphenyl)alanine; Tyrosine [USAN:INN]; Tyrosine, L-; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 3-(4-Hydroxyphenyl)-L-alanine; L-Tyrosin; FEMA No. 3736; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-(-)-Tyrosine; HSDB 2003; alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; AI3-09055; tirosina; Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-, (S)-; NSC 82624; L-tyrosinyl radical; alpha-Amino-p-hydroxyhydrocinnamic acid, (-)-; L-Tyr; (S)-2-Amino-3-(4-hydroxyphenyl)propanoic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; L-Tyrosine, monomer; alpha-Amino-4-hydroxybenzenepropanoic acid, (S)-; UNII-42HK56048U; Benzenepropanoic acid, alpha-amino-4-hydroxy-, (S)-; EINECS 200-460-4; MFCD00002606; 2-Amino-3-(4-hydroxyphenyl)propanoic acid, (S)-; CHEBI:17895; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; OUYCCCASQSFEME-QMMMGPOBSA-N; 42HK56048U; tyr; NCGC00159350-02; Tyrosine (L-Tyrosine); Tyrosinum; L-Tyrosine, 99+%; DSSTox_CID_3730; DSSTox_RID_77170; DSSTox_GSID_23730; L-Tyrosine, homopolymer; CAS-60-18-4; L-Tyrosine (9CI); 4ts1; Tyrosine (USP/INN); Benzenepropanoate; NSC-82624; 2csm; (L)-Tyrosine; (-) tyrosine; H-Tyr; L-Tyrosine,(S); (-)-.alpha.-Amino-p-hydroxyhydrocinnamic acid; PubChem14347; L-Tyrosine (JP17); Tyrosine, L- (8CI); .alpha.-Amino-.beta.-(4-hydroxyphenyl)propionic acid; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; bmse000051; CHEMBL925; SCHEMBL1581; L-[U-14C]Tyr; L-Phenylalanine-4-hydroxy-; KSC270I0D; Levodopa impurity, l-tyrosine-; GTPL4791; L-Tyrosine, >=97%, FG; DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; DTXSID1023730; BDBM18129; CTK1H0401; ZINC266964; N-acetyl-o-(dihydroxymethylsilyl)-; HY-N0473; L-Tyrosine, Vetec(TM), 98.5%; Levodopa related compound l-tyrosine; Tox21_111594; (-)-a-Amino-p-hydroxyhydrocinnamate; ANW-33439; s4608; AKOS010400205; Tox21_111594_1; (S)-a-Amino-4-hydroxybenzenepropanoate; AB00245; AM82304; CS-8013; DB00135; LS-2336; MCULE-2932088896; RTR-037233; (-)-alpha-Amino-p-hydroxyhydrocinnamate; (-)-a-Amino-p-hydroxyhydrocinnamic acid; (S)-a-amino-4-hydroxy-Benzenepropanoate; NCGC00159350-03; NCGC00344525-01; 25619-78-7; AC-11295; AK-93419; AS-11772; BP-13285; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; (S)-alpha-Amino-4-hydroxybenzenepropanoate; L-Tyrosine, BioUltra, >=99.0% (NT); (S)-2-Amino-3-(p-hydroxyphenyl)propionate; (S)-a-Amino-4-hydroxybenzenepropanoic acid; AB0010718; AB1002647; DB-029987; ST2413196; TR-037233; (S)-a-amino-4-hydroxy-Benzenepropanoic acid; (S)-alpha-amino-4-hydroxy-Benzenepropanoate; FT-0628034; L-Tyrosine, reagent grade, >=98% (HPLC); L-Tyrosine, SAJ special grade, >=99.0%; Y9454; C00082; D00022; L-Tyrosine, Vetec(TM) reagent grade, >=98%; M-3936; M02963; (2S)-2-amino-3-(4-hydroxyphenyl)propanoicacid; (S)-alpha-amino-4-hydroxy-Benzenepropanoic acid; 88844-EP2289892A1; 88844-EP2305825A1; (S)-.alpha.-Amino-4-hydroxybenzenepropanoic acid; 002T606; 2-Amino-3-(4-hydroxyphenyl)propanoic acid-(S)-; Q188017; J-521656; Propanoic acid, 2-amino-3-(4-hydroxyphenyl)-(S)-; Q27115106; Benzenepropanoic acid, .alpha.-amino-4-hydroxy-, (S)-; F8889-8713; L-Tyrosine, certified reference material, TraceCERT(R); Tyrosine, European Pharmacopoeia (EP) Reference Standard; Z1250208672; UNII-0O72R8RF8A component OUYCCCASQSFEME-QMMMGPOBSA-N; UNII-A9BAT9B32M component OUYCCCASQSFEME-QMMMGPOBSA-N; UNII-N7U7BXP2OI component OUYCCCASQSFEME-QMMMGPOBSA-N; L-Tyrosine, United States Pharmacopeia (USP) Reference Standard; 2-amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-Propanoate; 2-amino-3-(4-hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-Propanoic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; L-Tyrosine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, >=99.0%; L-Tyrosine, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; Tyrosine; AI3-09055
Lactic acid 2-Hydropropanoic acid; 2-Hydroxypropanoic acid; AI3-03130
Lanosterol (3beta)-Lanosta-8,24-dien-3-ol; lanosterol; 79-63-0; Lanosterin; Lanster; Botalan base 138; Lanosta-8,24-dienol; (3beta)-lanosta-8,24-dien-3-ol; Lanosta-8,24-dien-3beta-ol; Lanosta-8,24-dien-3-ol; UNII-1J05Z83K3M; NSC60677; Botalan base; CHEBI:16521; CAHGCLMLTWQZNJ-BQNIITSRSA-N; Lanosta-8,24-dien-3.beta.-ol; 1J05Z83K3M; MFCD00021108; Lanostadien-3-beta-ol; NSC 60677; Lanosta-8,24-dien-3-ol, (3beta)-; Lanosta-8,24-dien-3-ol, (3.beta.)-; Lanosta-8,24-dien-3-beta-ol; 4,4',14alpha-Trimethyl-5alpha-cholesta-8,24-dien-3beta-ol; EINECS 201-214-9; Cholesta-8,24-dien-3-ol, 4,4,14-trimethyl-, (3.beta.,5.alpha.)-; (3-beta)-Lanosta-8,24-dien-3-ol; BRN 2226449; AI3-23643; Lanostereol; Cholesta-8,24-dien-3-ol, 4,4,14-trimethyl-, (3beta,5alpha)-; (3.beta.)-Lanosta-8,24-dien-3-ol; Lanosta-8,24-dien-3-ol, (3-beta)-; 8,24-Lanostadien-3beta-ol; Lanosta-8, (3.beta.)-; Lanosterol, >=93%, powder; SCHEMBL145834; CHEMBL225111; GTPL2746; DTXSID1040744; 3beta-Hydroxy-8,24-lanostadiene; ZINC3870056; LMST01010017; NSC-60677; s4755; (3 beta)-Lanosta-8,24-dien-3-ol; AKOS024307002; DB03696; HY-W020033; Lanosta-8,24-dien-3beta-ol (8CI); MCULE-6692951185; NCGC00164398-01; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3beta,20R)-Lanosta-8,24-dien-3-ol; CS-0031956; FT-0627682; 7073-EP2277507A1; 7073-EP2286795A1; 7073-EP2298776A1; C01724; Q414996; (3alpha)-4,4,14-trimethyl-Cholesta-8,24-dien-3-ol; (3beta,5alpha)-4,4,14-trimethylcholesta-8,24-dien-3-ol; 4,4,14alpha-trimethyl-5alpha-cholesta-8,24-dien-3beta-ol; C4CA2F34-1C1A-4673-AC43-E547708CB228; Cholesta-8, 4,4,14-trimethyl-, (3.beta.,5.alpha.)-; UNII-U431865SO1 component CAHGCLMLTWQZNJ-BQNIITSRSA-N; (3beta,5alpha)-4,4,14-trimethyl-Cholesta-8,24-dien-3-ol; (3S,5R,10S,13R,14R,17R)-17-[(1R)-1,5-dimethylhex-4-enyl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,5R,10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-17-((R)-6-methylhept-5-en-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; Lanosta-8,24-dien-3-ol, (3beta)-; 4-06-00-04188 (Beilstein Handbook Reference)
Lapachol 2-Hydroxy-3-(3-methyl-2-buten-1-yl)-1,4-naphthalenedione; Lapachol; C.I. 75490
Lasalocid 6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-Ethyl-5-[(2R,5R,6S)-5-ethyltetrahydro-5-hydroxy-6-methyl-2H-pyran-2-yl]tetrahydro-3-methyl-2-furanyl]-4-hydroxy-3,5-dimethyl-6-oxononyl]-2-hydroxy-3-methylbenzoic acid; Lasalocid; X 537A
Latrunculin B (4R)-4-[(1R,4Z,8Z,10S,13R,15R)-15-Hydroxy-5,10-dimethyl-3-oxo-2,14-dioxabicyclo[11.3.1]heptadeca-4,8-dien-15-yl]-2-thiazolidinone; Latrunculin B; LAT-B
Lauramine oxide Amine oxide; N,N-Dimethyl-1-dodecanamine-N-oxide; 4-04-00-00798 (Beilstein Handbook Reference)
Lauric acid Dodecanoic acid; C-1297
Letrozole 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile; letrozole; 112809-51-5; Femara; 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozol; CGS 20267; CGS-20267; LETRAZOLE; Femera; Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-; 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile; UNII-7LKK855W8I; 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; HSDB 7461; C17H11N5; CHEMBL1444; 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile; 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile; 7LKK855W8I; CHEBI:6413; HPJKCIUCZWXJDR-UHFFFAOYSA-N; MFCD00866241; 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile; NCGC00016973-01; Letoval; CAS-112809-51-5; DSSTox_CID_3202; DSSTox_RID_76924; DSSTox_GSID_23202; Q-201291; Letrozole [USAN:INN]; SMR000466343; Femara (TN); SR-01000759382; Letrozole (JAN/USP/INN); CCRIS 8822; 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole; FEM-345; Femara, Letrozole; Letrozole [USAN:USP:INN:BAN]; CGS20267; Prestwick0_001025; Prestwick1_001025; Prestwick2_001025; Prestwick3_001025; Femara (TN) (Novartis); SCHEMBL4331; 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole; BIDD:PXR0130; BSPBio_001209; MLS000759455; MLS001424038; MLS002584991; MLS006010040; BIDD:GT0015; SPBio_003070; BPBio1_001331; GTPL5209; DTXSID4023202; Letrozole, >=98% (HPLC); BDBM13061; CTK8B5413; EX-A965; QCR-225; HMS1571M11; HMS2051E08; HMS2089L22; HMS2098M11; HMS2233C23; HMS3369E11; HMS3393E08; HMS3651K05; HMS3715M11; Pharmakon1600-01502354; BCP23354; CGS-20267 pound>>LETROZOLE; KS-00000XA8; ZINC3778874; Tox21_110719; Tox21_303572; ABP001083; ANW-48664; BG0620; NSC719345; NSC759652; s1235; STL451047; AKOS005145822; AB07525; AC-1193; API0024524; BCP9000848; CCG-100849; CS-1776; DB01006; KS-1269; NC00099; NSC-719345; NSC-759652; RTC-070977; NCGC00016973-02; NCGC00016973-03; NCGC00016973-06; NCGC00257460-01; 4CA-0737; BR-59607; CPD000466343; HY-14248; LS-38788; SAM001246649; SC-00402; BCP0726000213; AB0012832; AB1009309; AX8041188; ST2405214; 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole; 4,2,4-Triazol-1-ylmethylene)dibenzonitrile; AB00514009; FT-0627797; L0248; SW197294-4; A25380; C08163; D00964; EN300-264820; J10423; S-4137; AB00514009-05; AB00514009-07; AB00514009-08; AB00514009-09; AB00514009_10; AB00514009_11; 809L515; Q194974; W-60273; 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile; SR-01000759382-4; SR-01000759382-5; BRD-K88789588-001-03-2; 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile; 4,4'-(1h-1,2,4-triazol-1-ylmethylene)-bisbenzonitrile; F2173-0288; Z1741968261; Letrozole, European Pharmacopoeia (EP) Reference Standard; Letrozole, United States Pharmacopeia (USP) Reference Standard; 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE; Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material; 4,4 inverted exclamation marka-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile; Letrozole; Letrozole
Leukotriene B4 [S-[R*,S*-(E,E,Z,Z]]-5,12-Dihydroxy-6,8,10,14-eicosatetraenoic acid; Leukotriene B4; 5,12-Dihete
Levmetamfetamine N,alpha-Dimethyl-L-phenethylamine; Levmetamfetamine [USAN:USP:INN]; Benzeneethanamine, N,alpha-dimethyl-, (-)-
Levocarnitine (2R)-3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium inner salt; 3-Carboxy-2-hydroxy-N,N,N-trimethyl-1-propanaminium hydroxide, inner salt; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, L-
Levodopa 3-Hydroxy-L-tyrosine; levodopa; L-dopa; 59-92-7; 3,4-dihydroxy-L-phenylalanine; 3-Hydroxy-L-tyrosine; Dopar; Larodopa; Bendopa; Levopa; Cidandopa; Insulamina; Maipedopa; Dopaidan; Dopalina; Dopasol; Eldopal; Eldopar; Pardopa; Prodopa; Syndopa; 3-(3,4-Dihydroxyphenyl)-L-alanine; 3,4-Dihydroxyphenylalanine; (-)-Dopa; Dihydroxy-L-phenylalanine; Helfo-Dopa; Brocadopa; Dopaflex; Deadopa; Dopal-fher; Doparkine; Dopaston; Dopastral; Eldopatec; Eurodopa; Doparl; Doprin; Veldopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; L-3,4-Dihydroxyphenylalanine; Dopa; Levedopa; L-o-Hydroxytyrosine; Levodopum; Ledopa; (-)-3-(3,4-Dihydroxyphenyl)-L-alanine; L-Tyrosine, 3-hydroxy-; 3,4-Dihydroxyphenyl-L-alanine; Dopaston SE; beta-(3,4-Dihydroxyphenyl)-L-alanine; L-(o-Dihydroxyphenyl)alanine; L-(-)-Dopa; L-3-Hydroxytyrosine; L-beta-(3,4-Dihydroxyphenyl)alanine; Biodopa; Cerepap; Sobiodopa; Weldopa; Parda; L-Dihydroxyphenylalanine; Helfo DOPA; Ro 4-6316; beta-(3,4-Dihydroxyphenyl)alanine; L-3-(3,4-Dihydroxyphenyl)alanine; Tyrosine, 3-hydroxy-; C9H11NO4; Levodopum [INN-Latin]; L-O-Dihydroxyphenylalanine; alanine, 3-(3,4-dihydroxyphenyl)-, L-; component of Sinemet; CCRIS 3766; Dopar (TN); (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid; CHEBI:15765; HSDB 3348; beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine; L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine; UNII-46627O600J; 3,4-Dihydroxyphenylalanine (VAN); Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-; L(-)-Dopa; (-)-(3,4-Dihydroxyphenyl)alanine; EINECS 200-445-2; MFCD00002598; NSC 118381; L-3,4-Dihydrophenylalanine; L-.beta.-(3,4-Dihydroxyphenyl)alanine; CHEMBL1009; .beta.-(3,4-Dihydroxyphenyl)-L-alanine; beta-(3,4-Dihydroxyphenyl)-alpha-alanine; L-(3,4-Dihydroxyphenyl)alanine; CVT-301; dihydroxyphenylalanine; WTDRDQBEARUVNC-LURJTMIESA-N; NSC118381; .beta.-(3,4-Dihydroxyphenyl)alanine; NSC-118381; CAS-59-92-7; NCGC00016270-04; L-(3,4-Dihydroxyphenyl)-.alpha.-alanine; 46627O600J; 587-45-1; Laradopa; Atamet; BDBM50130192; L Dopa; 3-(3,4-Dihydroxyphenyl)-L-alanine, 99%; WLN: QVYZ1R CQ DQ; SR-01000075384; Dopastone; Dopicar; Inbrija; Prolopa; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; IV Levodopa; Levodopa [USAN:INN:BAN:JAN]; Prestwick_185; Levodopa (Sinemet); L-DOPA; Levodopa; Madopa (Salt/Mix); Levodopa [USAN:USP:INN:BAN:JAN]; Spectrum_000454; Carbidopa EP Impurity A; Prestwick0_000017; Prestwick1_000017; Prestwick2_000017; Prestwick3_000017; Spectrum2_000496; Spectrum4_000539; Spectrum5_001899; Lopac-D-9628; Levodopa (JP15/USP); DSSTox_CID_3209; bmse000322; Epitope ID:150927; 3, 4-Dihydroxyphenylalanine; Alanine,4-dihydroxyphenyl)-; DSSTox_RID_76926; DSSTox_GSID_23209; Lopac0_000454; SCHEMBL22655; BSPBio_000053; BSPBio_002354; KBioGR_001177; KBioSS_000934; L-4-5-Dihydroxyphenylalanine; MLS000028514; BIDD:GT0158; DivK1c_000452; SPECTRUM2300205; Levodopa (JP17/USP/INN); SPBio_000391; SPBio_001974; BPBio1_000059; GTPL3639; (S)-3,4-dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)alanine; DTXSID9023209; WLN: QVYZ1R CQ DQ -L; 3, 4-Dihydroxy-L-phenylalanine; BDBM60928; CTK1H2187; HMS501G14; KBio1_000452; KBio2_000934; KBio2_003502; KBio2_006070; Alanine,4-dihydroxyphenyl)-, L-; L-(3, 4-Dihydroxyphenyl)alanine; NINDS_000452; HMS1568C15; HMS1922J14; HMS2090O08; HMS2093N04; HMS2095C15; HMS2230B04; HMS3261K10; HMS3712C15; Pharmakon1600-02300205; ZINC895199; H-Phe{3,4-(OH)2}-OH; HY-N0304; Levodopa; 3,4-Dihydroxyphenylalanine; b-(3,4-Dihydroxyphenyl)-L-alanine; Inbrija (levodopa inhalation powder); Tox21_110338; Tox21_500454; ANW-33396; CCG-39571; KM0355; L-3-(3,4-dihydroxy-phenyl)alanine; L-3-(3,4-dihydroxyphenyl)-Alanine; LS-255; NSC759573; PDSP1_001541; PDSP2_001525; s1726; SBB017533; Alanine, 3-(3,4-dihydroxyphenyl)-; Alanine,4-dihydroxyphenyl)-, (-)-; AKOS010396267; b-(3,4-Dihydroxyphenyl)-a-L-alanine; L-b-(3,4-Dihydroxyphenyl)-a-alanine; .beta.-(3, 4-Dihydroxyphenyl)alanine; AC-8432; AM82124; CS-1945; DB01235; LP00454; MCULE-4743781842; NSC-759573; RTR-020755; SDCCGMLS-0066924.P001; SDCCGSBI-0050439.P004; VA11170; IDI1_000452; NCGC00015384-01; NCGC00016270-01; NCGC00016270-06; NCGC00016270-07; NCGC00016270-09; NCGC00016270-10; NCGC00093869-04; NCGC00261139-01; AK187821; AS-13287; BP-12850; H813; SC-10704; SMR000058312; ST086623; SBI-0050439.P003; AB0013279; AB1009504; L-(3, 4-Dihydroxyphenyl)-.alpha.-alanine; TR-020755; D0600; D9628; EU-0100454; FT-0603250; N1648; 59L927; Alanine, 3-(3, 4-dihydroxyphenyl)-, (-)-; C00355; D 9628; D00059; J10404; V-1512; 13173-EP2269989A1; 13173-EP2277876A1; 13173-EP2277882A1; 13173-EP2281559A1; 13173-EP2281815A1; 13173-EP2292614A1; 13173-EP2295412A1; 13173-EP2295413A1; 13173-EP2295439A1; 13173-EP2298731A1; 13173-EP2301933A1; 13173-EP2301934A1; 13173-EP2305633A1; 13173-EP2305640A2; 13173-EP2308867A2; 13173-EP2308870A2; 13173-EP2311827A1; 13173-EP2311837A1; 13173-EP2314571A2; 13173-EP2316470A2; 13173-EP2316834A1; 21660-EP2272832A1; 21660-EP2275420A1; 21660-EP2281559A1; 21660-EP2301934A1; 21660-EP2314571A2; 21920-EP2295410A1; 21920-EP2301939A1; 21920-EP2314571A2; 3,4-Dihydroxy-L-phenylalanine, >=98% (TLC); AB00052418-06; AB00052418-07; AB00052418_08; AB00052418_09; Q300989; Q-201294; SR-01000075384-1; SR-01000075384-4; SR-01000075384-6; SR-01000075384-7; (S)-2-Amino-3-(3,4-dihydroxy-phenyl)-propionic acid; F0347-4695; Levodopa, British Pharmacopoeia (BP) Reference Standard; Levodopa, European Pharmacopoeia (EP) Reference Standard; Z1762772338; (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acidL-dopa; UNII-QI9C343R60 component WTDRDQBEARUVNC-LURJTMIESA-N; 1E83F927-C221-46AA-B90A-81B33C5F3868; 3,4-Dihydroxy-L-phenylalanine, Vetec(TM) reagent grade, 98%; Levodopa, United States Pharmacopeia (USP) Reference Standard; L-3-(3,4-Dihydroxyphenyl)alanine（ L-DOPA ） 3,4-Dihydroxy-L-phenylalanine, certified reference material, TraceCERT(R); 3-(3,4-Dihydroxyphenyl)-L-alanine; L-3-Hydroxytyrosine; L-DOPA; Levodopa; Levodopa, Pharmaceutical Secondary Standard; Certified Reference Material; L-Methyldopa; (2S)-2-Amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid; 3-(3,4-Dihydroxyphenyl)-?-methyl-L-alanine; 3-Hydroxy-a-methyl-L-tyrosine; Levodopa; Alanine, 3-(3,4-dihydroxyphenyl)-, (-)-
Levofloxacin (3S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; Levofloxacin [USAN:INN:JAN]; CCRIS 4074
Levonordefrin 4-[(1R,2S)-2-Amino-1-hydroxypropyl]-1,2-benzenediol; Nordefrin, (-)-; Corbadrina [INN-Spanish]
Levonorgestrel (17alpha)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one; Levonorgestrel; BRN 2391114